BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy
Bristol Myers Squibb is paying $50 million to begin a collaboration with Janux Therapeutics, a company that develops T cell engagers that activate specifically at the site of the tumor. It’s the second big pharma alliance for Janux, which has been working with Merck.
TEAM is Here, and Hospitals Are Running Out of Time to Prepare
Organizations can take steps now, in the early months of the program, to position themselves for success by evaluating past performance, identifying opportunities for improvement, and implementing episode-driven clinical and operational workflows.
Regulations Needed to Improve Clinical Adoption Of CBD as Medicine
There must be clear rules and regulations in effect if we are to see medical-grade CBD become widely accepted amongst clinicians.